Dana-Farber Cancer Institute | Strategic Alliance Partners

September 26, 2024

Oncology experts share their key takeaways in genitourinary cancers and recent updates from the 2024 ESMO Congress.

September 25, 2024

Ann H. Partridge, MD, MPH, discusses unique challenges associated with very young patients who have ER+/node-positive breast cancer.

September 23, 2024

The SOLARIS trial results suggest that high-dose vitamin D3 cannot be recommended as a treatment for patients with untreated metastatic colon cancer.

September 18, 2024

Alicia Morgans, MD, MPH, discusses prior data and follow-up analysis of the ARAMIS trial in nonmetastatic castration-resistant prostate cancer.

September 16, 2024

Paolo Tarantino, MD, discusses advancements that may lead to more tailored treatment approaches in early-stage HER2+ breast cancer.

September 15, 2024

Toni Choueiri, MD, discusses findings with tivozanib plus nivolumab in metastatic RCC after progression on an immune checkpoint inhibitor.

September 14, 2024

Nancy U. Lin, MD, discusses the DESTINY-Breast12 trial of T-DXd in patients with HER2-positive metastatic breast cancer with or without brain metastases.

September 13, 2024

The addition of nivolumab to tivozanib did not improve outcomes in metastatic RCC and 1.34 mg of tivozanib monotherapy may be considered as a second-line therapy.

September 12, 2024

Laurie H. Glimcher, MD, announced today that she will step down as Dana-Farber Cancer Institute President and CEO on October 1, 2024, and will assume the title of President Emerita.

September 11, 2024

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ESMO Congress.

September 09, 2024

Dato-DXd did not significantly improve overall survival compared with docetaxel for patients with non–small cell lung cancer.

September 09, 2024

The study alters the existing paradigm that CDK1-Cyclin B1 is the only CDK-cyclin complex essential for all stages of mitosis.

September 06, 2024

Systematic identification of minor histocompatibility antigens informs outcomes after allogeneic stem cell transplantation.

September 06, 2024

Bradley McGregor, MD, discusses the current NCCN guideline recommendations for the treatment of patients with divergent RCC histologies.

September 05, 2024

Reid Merryman, MD, discusses the evolution of minimal residual disease assays in lymphoma.

September 05, 2024

Dr Florez discusses ways that she helps patients with lung cancer understand the importance of biomarker testing.

September 05, 2024

The panel concludes by offering final thoughts and insights on recent advancements from EHA 2024.

September 04, 2024

Emre Yekedüz, MD, discusses a case study shared via social media that evaluated treatment options for a patient with clear cell renal cell carcinoma.

September 04, 2024

Rashad Nawfal, MD, discusses the association between radiologic tumor burden and OS in patients with metastatic ccRCC who had received frontline IO.

September 03, 2024

Sara M. Tolaney, MD, MPH, discusses the utility of TROP2-directed antibody-drug conjugates in the treatment of patients with breast cancer.